Health and Healthcare
Pfizer (PFE) Does Some Good, Viagra Rocks On
Published:
Last Updated:
Once all of the one-time charges were washed out of the numbers, Pfizer recorded adjusted income of $4.2 billion, an increase of 5% compared with $4.0 billion in the year-ago quarter, and EPS of $.62, an increase of 7% compared with $.58 in the year-ago quarter. The firm hit these numbers despite a drop in sales of its Zyrtec and Camptosar products.
Viagra and Lipitor continued to do well, a bit of a commentary on life in the US in 2008.
Perhaps most important, Pfizer upped its forecasts. The pharma firm raised the lower end of its guidance range for full-year 2008 revenues to $48.0 to $49.0 billion from $47.0 to $49.0 billion.
All in all, a pretty outstanding set of numbers
Douglas A. McIntyre
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.